All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb and Incyte. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View MPN content recommended for you
Should we consider early testing and treatment for driver mutations acquired in childhood?
Featured:
Jyoti NangaliaDuring the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to Jyoti Nangalia, University of Cambridge, Cambridge, UK. We asked, Should we consider early testing and treatment for driver mutations acquired in childhood?
Should we consider early testing and treatment for driver mutations acquired in childhood?
In this podcast, Jyoti Nangalia reports results from a study using next-generation sequencing to trace acquired MPN mutations in hematopoietic stem cells taken from patients with varying stages of disease presentation. Nangalia discusses unexpected results, such as the acquisition of key driver mutations (JAK2 and DNMT3A) very early in life. She also discusses results observing a variation in the growth rate of cancer cell clones between patients, as well as the correlation of growth rate with disease presentation. Nangalia concludes with possible future applications of these methods in the early detection and prevention of MPN.